Cargando...
Impact of patient characteristics on the clinical efficacy of mongersen (GED‐0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
BACKGROUND: In a phase 2 study, mongersen, an oral antisense oligonucleotide targeting Smad7, was effective in inducing clinical remission in approximately 60% of patients with active Crohn's disease (CD). AIM: In a post hoc analysis to evaluate those patient disease characteristics that may ha...
Guardado en:
| Publicado en: | Aliment Pharmacol Ther |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4849204/ https://ncbi.nlm.nih.gov/pubmed/26766141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.13526 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|